v3.26.1
REVERSE MERGER (Tables)
 3 Months Ended
Jun. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
SCHEDULE OF PURCHASE PRICE ALLOCATION

The allocation of the purchase price of the assets acquired and liabilities assumed for the acquisition by Phytanix Bio of Protagenic Therapeutics, Inc. via the reverse acquisition are set forth below:

 

Purchase Price Allocation of Protagenic Therapeutics, Inc.

 

      
Current assets – cash and prepaid  $1,029,985 
Intangible assets – in process research and development and assembled workforce   2,093,228 
Fixed assets   76,550 
Accounts payable and accrued expenses   (857,504)
Purchase price  $2,342,259 
SCHEDULE OF BUSINESS COMBINATION CONTINGENT CONSIDERATION

 SCHEDULE OF BUSINESS COMBINATION CONTINGENT CONSIDERATION

   Amount 
Cash  $310,000 
Receipt of Company shares   (41,192)
Total Consideration (Fair Value)  $268,808 

 

Net assets calculation

 

   Amount 
Total Assets of Phytanix  $62,103 
Less: Total Liabilities of Phytanix   7,641,630 
Net Liabilities Deconsolidated  $(7,579,527)

 

Gain/(loss) calculation

 

   Amount 
Total Consideration  $268,808 
Less: Net Assets Deconsolidated   7,579,527 
Gain on disposal of subsidiary  $(7,310,719)